ES2320204T3 - Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos. - Google Patents
Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos. Download PDFInfo
- Publication number
- ES2320204T3 ES2320204T3 ES02738100T ES02738100T ES2320204T3 ES 2320204 T3 ES2320204 T3 ES 2320204T3 ES 02738100 T ES02738100 T ES 02738100T ES 02738100 T ES02738100 T ES 02738100T ES 2320204 T3 ES2320204 T3 ES 2320204T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- cycloalkyl
- phenyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Abstract
Compuestos de la fórmula general I** ver fórmula** en la que R1 significa halógeno R2 representa -CH(CH3)-(CH2)n-R 5 , -CH-(CH2OH)2, -(CH2)nR 7 , -CH(C3H7)-(CH2)n-R 5 , -CH(C2H5)-(CH2)n- R 5 , -CH 2-CN, -CH(CH 3)COCH 3, -CH(CH 3)-C(OH)(CH 3) 2, -CH(CH(OH)CH 3)OCH 3, -CH(C 2H 5)CO-R 5 , alquinilo de C 2-C 4, -(CH 2) n-COR 5 , -(CH 2) n-CO-alquilo de C 1-C 6, -(CH 2) n-C(OH)(CH 3)-fenilo (Ph), -CH (CH3)-C(CH3)-R 5 , -CH(CH3)-C(CH3)(C2H5)-R 5 , -CH(OCH3)-CH2-R 5 , -CH2-CH(OH)-R 5 , -CH(OCH3)- CHR 5 -CH3, -CH(CH3)-CH(OH)-CH2-CH=CH2, -CH(C2H5)-CH(OH)-(CH2)n-CH3, -CH(CH3)-CH(OH)- (CH2)n-CH3, -CH(CH3)-CH(OH)-CH(CH3)2, (CH2OAC)2, -(CH2)n-R 6 , -(CH2)n-(CF2)n-CF3, -CH(CH2)n- R 5 ) 2, -CH(CH 3)-CO-NH 2, -CH(CH 2OH)-fenilo,- CH(CH 2OH)-CH(OH)-(CH 2) nR 5 , -CH(CH 2OH)CH(OH)fenilo, -CH(CH 2OH)-C 2H 4-R 5 , -(CH 2) n-C*C-C(CH 3)=CH-COR 5 , -CH(Ph)-(CH 2) n-R 5 -(CH 2) n-COR 5 , -(CH2)nPO3(R 5 )2, -(CH2)n-COR 5 , -CH((CH2)nOR 5 )CO-R 5 , -(CH2)nCONHCH((CH2)nR 5 )2, -(CH2)nNH- COR 5 , -CH(CH2)nR 5 -(CH2)n-cicloalquilo de C3-C10, -(CH2)n-cicloalquilo de C3-C10, cicloalquilo de C3- C10, alquilo de C1-C6 eventualmente sustituido una vez o múltiples veces, de igual o diferente manera, con hidroxi, alquilo de C 1-C 6 o con el grupo -COONH(CH 2) nCH 3 o -NR 3 R 4 , cicloalquilo de C 3-C 10, -(CH 2) n-O- (CH 2)n-R 5 , -(CH 2) n-NR 3 R 4 , -CH(C 3H 7)-(CH 2) n-OC(O)-(CH 2) n-CH 3, -(CH 2) n-R 5 , -C(CH 3) 2-(CH 2) n-R 5 , -C (CH2)n(CH3)-(CH2)nR 5 , -C(CH2)n-(CH2)nR 5 , -CH(t-butil)-(CH2)n-R 5 , -CCH3(C3H7)-(CH2)nR 5 , -CH(C3H7)- (CH2)n-R 5 , -CH(C3H7)-COR 5 , -CH(C3H7)-(CH2)n-OC(O)-NH-Ph, -CH((CH2)n(C3H7))-(CH2)nR 5 , -CH (C3H7)-(CH2)n-OC(O)-NH-Ph(OR 5 )3, -NR 3 R 4 , -NH-(CH2)n-NR 3 R 4 , R 5 -(CH2)n-C*H-CH(R 5 )(CH2)n-R 5 , -(CH 2) n-CONH-(CH 2) n-CO-R 5 , -OC(O)NH-alquilo de C 1-C 6 o -(CH 2) n-CO-NH-(CH 2) n-CH-((CH 2) nR 5 ) 2, o representa un cicloalquilo de C 3-C 10, que está sustituido con el grupo** ver fórmula** o representa el grupo ** ver fórmula** X representa oxígeno o representa el grupo -NH- o -N(alquilo de C 1-C 3), o R 2 representa el grupo** ver fórmula** X y R 2 forman en común un grupo ** ver fórmula** A representa el grupo -SO 2R 7, SO 2-C 2H 4-OH, -SO 2CF 3 o -SO 2-NR 3 R 4 , B representa hidrógeno, hidroxi o alquilo de C1-C3 o A y B pueden formar en común un grupo ** ver fórmula** R 3 y R 4 representan, en cada caso independientemente uno de otro, hidrógeno, fenilo, benciloxi, alquilo de C1-C12, alcoxi de C1-C6, alqueniloxi de C2-C4, cicloalquilo de C3-C6, hidroxi, hidroxi-alquilo de C1-C6, dihidroxialquilo de C1-C6, heteroarilo, heterociclo-alquilo de C3-C10, heteroaril-alquilo de C1-C3, cicloalquil de C3- C 6-alquilo de C 1-C 3 eventualmente sustituido con ciano, o representan alquilo de C 1-C 6 eventualmente sustituido una vez o múltiples veces, de igual o diferente manera con fenilo, piridilo, feniloxi, cicloalquilo de C3-C6, alquilo de C1-C6 o con alcoxi de C1-C6, pudiendo el propio fenilo estar sustituido una vez o múltiples veces, de igual o diferente manera, con halógeno, trifluorometilo, alquilo de C1-C6, alcoxi de C1- C6 o con el grupo -SO2NR 3 R 4 , o representan el grupo -(CH 2) nNR 3 R 4 , -CNHNH 2 o -NR 3 R 4 o representan** ver fórmula** que eventualmente pueden estar sustituidos con alquilo de C 1-C 6, R 5 representa hidroxi, fenilo, alquilo de C1-C6, cicloalquilo C3-C6, benzoxi, alquiltio de C1-C6 o alcoxi de C1- C6, R 6 representa el grupo ** ver fórmula** R 7 representa halógeno, hidroxi, fenilo, alquilo de C1-C6, -(CH2)nOH, -NR 3 R 4 o el grupo R 8 , R 9 y R 10 representan hidrógeno, hidroxi, alquilo de C1-C6 o el grupo -(CH2)n-COOH, y n representa 0-6 así como sus diastereoisómeros, enantiómeros y sales.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10127581A DE10127581A1 (de) | 2001-05-29 | 2001-05-29 | CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10127581 | 2001-05-29 | ||
DE10212098A DE10212098A1 (de) | 2002-03-11 | 2002-03-11 | CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
DE10212098 | 2002-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2320204T3 true ES2320204T3 (es) | 2009-05-20 |
Family
ID=26009483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02738100T Expired - Lifetime ES2320204T3 (es) | 2001-05-29 | 2002-05-23 | Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos. |
Country Status (23)
Country | Link |
---|---|
US (3) | US7235561B2 (es) |
EP (1) | EP1392662B1 (es) |
JP (1) | JP4291135B2 (es) |
KR (1) | KR100874791B1 (es) |
CN (1) | CN100480242C (es) |
AR (1) | AR036035A1 (es) |
AT (1) | ATE420077T1 (es) |
AU (1) | AU2002312933B2 (es) |
BR (1) | BR0209774A (es) |
CA (1) | CA2449118A1 (es) |
CO (1) | CO5540316A2 (es) |
DE (1) | DE50213202D1 (es) |
ES (1) | ES2320204T3 (es) |
HR (1) | HRP20031081A2 (es) |
IL (1) | IL159120A0 (es) |
ME (1) | MEP13408A (es) |
MX (1) | MXPA03010810A (es) |
NO (1) | NO327129B1 (es) |
NZ (1) | NZ529654A (es) |
PL (1) | PL367130A1 (es) |
RS (1) | RS94703A (es) |
RU (1) | RU2330024C2 (es) |
WO (1) | WO2002096888A1 (es) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MEP13408A (en) * | 2001-05-29 | 2010-06-10 | Bayer Schering Pharma Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
AU2002316421B2 (en) * | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
AU2002367172A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
AU2003208479A1 (en) | 2002-03-09 | 2003-09-22 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
DK1534286T3 (da) | 2002-07-29 | 2010-04-26 | Rigel Pharmaceuticals Inc | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
NZ539823A (en) * | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
PL379330A1 (pl) | 2002-12-20 | 2006-08-21 | Pfizer Products Inc. | Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20040242613A1 (en) | 2003-01-30 | 2004-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
PT1656372E (pt) | 2003-07-30 | 2013-06-27 | Rigel Pharmaceuticals Inc | Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina |
ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP1694652A1 (en) * | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
AU2005231507B2 (en) * | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
CA2566332A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1758887A1 (en) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP2007537235A (ja) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療用ピリミジン誘導体 |
CA2566531A1 (en) * | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
US7534780B2 (en) * | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
US20050277625A1 (en) * | 2004-05-21 | 2005-12-15 | Ralf Wyrwa | Estriol and estetrol prodrugs |
JP2008505910A (ja) | 2004-07-08 | 2008-02-28 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | Pkc−シータのインヒビターとして有用なピリミジン誘導体 |
NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
JP2008514571A (ja) * | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換2−置換アニリノピリミジン類、それらの製造および薬剤としての使用 |
TW200626559A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Anilino-pyrimidine analogs |
GB2420559B (en) * | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US7557207B2 (en) | 2004-11-24 | 2009-07-07 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
CA2589793A1 (en) * | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as cdk inhibitors |
AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
CA2600531A1 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
EP1705177A1 (en) * | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
NZ563454A (en) * | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
MX2008001428A (es) * | 2005-07-30 | 2008-04-04 | Astrazeneca Ab | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. |
WO2007038387A2 (en) * | 2005-09-23 | 2007-04-05 | Yale University | Compounds and methods for the treatment of viruses and cancer |
DE102005048072A1 (de) * | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
KR20080049130A (ko) * | 2005-09-30 | 2008-06-03 | 아스트라제네카 아베 | 세포 증식 억제 활성을 갖는 이미다조 [1,2-a] 피리딘 |
US20070110751A1 (en) * | 2005-10-25 | 2007-05-17 | Maclellan Robb | Compositions and methods for reducing infarct size |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
MY167260A (en) * | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007056075A2 (en) * | 2005-11-02 | 2007-05-18 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
US20070197488A1 (en) * | 2005-11-29 | 2007-08-23 | Olaf Peters | Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds |
US20070123500A1 (en) * | 2005-11-29 | 2007-05-31 | Gerd Mueller | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds |
US20070135375A1 (en) * | 2005-11-30 | 2007-06-14 | Ralf Wyrwa | Sulfamoyl sulfonate prodrugs |
US20070135399A1 (en) * | 2005-11-30 | 2007-06-14 | Ralf Wyrwa | Heteroaromatic sulphonamide prodrugs |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
DE102006001161A1 (de) * | 2006-01-06 | 2007-07-12 | Qiagen Gmbh | Verfahren zum Nachweis von Cytosin-Methylierungen |
AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
PE20120006A1 (es) * | 2006-05-15 | 2012-02-02 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
CA2655315A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
CN101506175A (zh) * | 2006-06-15 | 2009-08-12 | 贝林格尔·英格海姆国际有限公司 | 作为蛋白激酶C-α抑制剂的2-苯氨基-4-(杂环基)氨基-嘧啶 |
EP1878726A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008051547A1 (en) | 2006-10-23 | 2008-05-02 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
EP1939185A1 (de) * | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
US20100144706A1 (en) | 2006-12-22 | 2010-06-10 | Boehringer Ingelheim International Gmbh | Compounds |
DE102007010801A1 (de) * | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
EP2146779B1 (en) | 2007-04-18 | 2016-08-10 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
WO2008140421A2 (en) * | 2007-05-15 | 2008-11-20 | S*Bio Pte Ltd | Heterocycloalkyl substituted pyrimidine derivatives |
KR101294731B1 (ko) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법 |
US20090030005A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combinations for the treatment of cancer |
WO2009089277A2 (en) * | 2008-01-08 | 2009-07-16 | The Trustees Of The University Of Pennsylvania | Rel inhibitors and methods of use thereof |
US20100056524A1 (en) * | 2008-04-02 | 2010-03-04 | Mciver Edward Giles | Compound |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
MX2010011463A (es) | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
EP2271631B1 (en) * | 2008-04-22 | 2018-07-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2010022125A1 (en) * | 2008-08-20 | 2010-02-25 | Schering Corporation | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
CA2735730A1 (en) * | 2008-09-01 | 2010-03-04 | Astellas Pharma Inc. | 2,4-diaminopyrimidine compound |
EP2161259A1 (de) * | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
EP2179993A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179991A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179992A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
DE102009001438A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
DE102009015070A1 (de) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
DE102010014426A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
EP2571867B1 (en) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Novel pyrimidine derivatives |
US8354420B2 (en) | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
US20140057908A1 (en) | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
PT3124483T (pt) | 2010-11-10 | 2019-10-02 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2 |
PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
KR20140006048A (ko) | 2011-03-24 | 2014-01-15 | 케밀리아 에이비 | 신규한 피리미딘 유도체 |
AU2012340555B2 (en) | 2011-11-23 | 2016-10-20 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
RU2647849C2 (ru) * | 2011-11-29 | 2018-03-21 | Дженентек, Инк. | Производные 2-(фенил или пирид-3-ил)аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) для лечения болезни паркинсона |
WO2013139734A1 (de) | 2012-03-21 | 2013-09-26 | Bayer Intellectual Property Gmbh | Verwendung von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung spezifischer tumore |
US9931400B2 (en) | 2012-09-12 | 2018-04-03 | Samsung Electronics Co., Ltd. | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases |
WO2014106606A1 (en) * | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
LT3126352T (lt) * | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
EP3242934B1 (en) | 2015-01-08 | 2021-08-18 | The Board of Trustees of the Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
CN108721307B (zh) * | 2018-03-20 | 2021-01-15 | 重庆医科大学 | Cdk2激酶抑制剂在制备乙型肝炎治疗药物中的应用 |
PL3902547T3 (pl) | 2018-12-28 | 2024-02-26 | Deciphera Pharmaceuticals, Llc | Inhibitory CSF1R do stosowania w leczeniu nowotworu złośliwego |
US20220153722A1 (en) * | 2019-04-04 | 2022-05-19 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
CA3132656A1 (en) | 2019-04-30 | 2020-11-05 | Instituto De Medicina Molecular Joao Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
CN111138417B (zh) * | 2019-12-18 | 2021-03-23 | 浙江工业大学 | 一种三氮唑修饰的5-氟-2,4-嘧啶二胺类化合物及其应用 |
CN112110863A (zh) * | 2020-08-27 | 2020-12-22 | 中山大学 | 一种磺酰氟类化合物、其制备方法以及通过其制备磺酰胺类化合物的方法 |
AU2021385745A1 (en) * | 2020-11-27 | 2023-06-15 | Allorion Therapeutics Inc | Aminoheteroaryl kinase inhibitors |
CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
WO2023226920A1 (en) * | 2022-05-27 | 2023-11-30 | Anrui Biomedical Technology (Guangzhou) Co.,Ltd. | Aminoheteroaryl kinase inhibitors |
CN115304550A (zh) * | 2022-07-25 | 2022-11-08 | 南通大学 | 哌嗪苯基氨基取代的嘧啶氨基酸衍生物及制备方法与应用 |
CN115232076A (zh) * | 2022-07-25 | 2022-10-25 | 南通大学 | 苯氨基取代的嘧啶氨基酸衍生物及其制备方法与应用 |
CN115304551A (zh) * | 2022-07-25 | 2022-11-08 | 南通大学 | 2-((4-吗啉苯基)氨基)嘧啶氨基酸衍生物及其制备方法与应用 |
WO2024059010A1 (en) * | 2022-09-13 | 2024-03-21 | Genesis Therapeutics, Inc. | Compounds for treating cancer |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947467A (en) * | 1973-08-02 | 1976-03-30 | Eli Lilly And Company | 3-(5-Nitro-2-imidazolyl) pyrazoles |
FR2257272B1 (es) * | 1974-01-15 | 1978-08-25 | Pharmascience Labo | |
DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
US4193926A (en) * | 1974-03-20 | 1980-03-18 | Schering Aktiengesellschaft | 4-(Polyalkoxy phenyl)-2-pyrrolidones |
DE2541855A1 (de) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
ATE798T1 (de) * | 1978-06-15 | 1982-04-15 | Imperial Chemical Industries Plc | Entzuendungshemmende 1-phe nyl-2-aminoaethanol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen zur oertlichen anwendung. |
EP0112707B1 (en) * | 1982-12-23 | 1987-11-04 | Smith Kline & French Laboratories Limited | Aminopyrimidinone derivatives as histamine h1-antagonists |
ATE60591T1 (de) * | 1984-06-25 | 1991-02-15 | Ciba Geigy Ag | Pyrimidinderivate wirksam als schaedlingsbekaempfungsmittel. |
JPH0629263B2 (ja) * | 1985-10-30 | 1994-04-20 | クミアイ化学工業株式会社 | ピリミジン誘導体および農園芸用殺菌剤 |
US4788195A (en) * | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
US4876252A (en) * | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
WO1987006576A1 (en) | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
US5128358A (en) * | 1988-01-19 | 1992-07-07 | Pfizer Inc. | Aryl substituted nitrogen heterocyclic antidepressants |
US4921862A (en) * | 1986-05-29 | 1990-05-01 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors |
US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
CN1030415A (zh) * | 1987-02-20 | 1989-01-18 | 山之内制药株式会社 | 饱和的杂环碳酰胺衍生物和它的制备方法 |
US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
US5274002A (en) * | 1987-04-14 | 1993-12-28 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
EP0310550B1 (de) * | 1987-09-28 | 1993-05-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
US4973690A (en) * | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
US4897396A (en) * | 1988-06-03 | 1990-01-30 | Ciba-Geigy Corporation | 2-phenylamino pyrimidine derivatives and their uses as microbicides |
ES2075202T3 (es) * | 1989-04-17 | 1995-10-01 | Byk Gulden Lomberg Chem Fab | Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen. |
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
JPH03127790A (ja) * | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
US5164078A (en) * | 1989-12-28 | 1992-11-17 | Chevron Research And Technology Company | Process for removal of calcium from a hydrocarbon feedstock |
DE4003919A1 (de) * | 1990-02-09 | 1991-08-14 | Basf Ag | Heteroarylalkene, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung |
GB9007762D0 (en) | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
WO1991016892A1 (en) | 1990-04-27 | 1991-11-14 | Rorer International (Holdings), Inc. | Styryl compounds which inhibit egf receptor protein tyrosine kinase |
EP0538384A4 (en) | 1990-07-10 | 1995-04-12 | Smithkline Beecham Corp | Oxamides |
US5124455A (en) * | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
DE4029650A1 (de) * | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
CA2091989A1 (en) | 1990-09-28 | 1992-03-29 | Roderick Alan Porter | Phenylpyridinol derivatives as medicaments |
DE59109027D1 (en) | 1990-10-16 | 1998-08-13 | Byk Gulden Lomberg Chem Fab | Arylpyridazinone |
WO1992007567A1 (en) | 1990-11-06 | 1992-05-14 | Smithkline Beecham Corporation | Imidazolidinone compounds |
GB9027055D0 (en) * | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
US5698711A (en) * | 1991-01-28 | 1997-12-16 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
EP0581805A1 (de) | 1991-04-26 | 1994-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridazine |
PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
EP0540165A1 (en) * | 1991-10-03 | 1993-05-05 | Zeneca Limited | Alkanoic acid derivatives |
DE4136921A1 (de) | 1991-11-11 | 1993-05-13 | Knoll Ag | Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure |
US5385963A (en) * | 1992-01-30 | 1995-01-31 | Gencorp Inc. | Unsaturated polyester-modified flexible copolymers for use in sheet molding compositions |
US5326898A (en) * | 1992-02-11 | 1994-07-05 | Allergan, Inc. | Substituted phenylethenyl compounds having retinoid-like biological activity |
DE69328778T2 (de) | 1992-04-02 | 2000-11-23 | Smithkline Beecham Corp | Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
GB9212673D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
WO1994002465A1 (en) | 1992-07-28 | 1994-02-03 | Rhone-Poulenc Rorer Limited | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF |
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
PT672031E (pt) | 1992-12-02 | 2003-06-30 | Pfizer | Dieteres de catecol como inibidores selectivos de pde iv |
ES2106155T3 (es) | 1992-12-07 | 1997-11-01 | Blangy Gerard De | Procedimiento y dispositivo de tratamiento y de valorizacion de desechos transformandolos en materiales no polucionantes y reutilizables. |
BR9307664A (pt) | 1992-12-17 | 1999-06-29 | Pfizer | Pirazóis substituídos como antagonistas |
US5622977A (en) * | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
TW263495B (es) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
EP0672041B1 (en) * | 1993-10-01 | 2001-11-14 | Novartis AG | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
ATE325113T1 (de) | 1993-10-01 | 2006-06-15 | Novartis Pharma Gmbh | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
CA2176255C (en) * | 1993-11-26 | 1999-02-23 | Edward F. Kleinman | Isoxazoline compounds as antiinflammatory agents |
GB9326699D0 (en) * | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
GB9326173D0 (en) * | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
JP3806144B2 (ja) * | 1993-12-22 | 2006-08-09 | セルテック セラピューティックス リミテッド | 三置換フェニル誘導体、その調製方法とホスホジエステラーゼ(iv型)阻害剤としてのその使用 |
US5691376A (en) * | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
CN1149870A (zh) | 1994-06-06 | 1997-05-14 | 辉瑞大药厂 | 具有促皮质激素释放因子拮抗剂活性的取代的吡唑 |
US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412573D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412571D0 (en) * | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) * | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
ES2219670T3 (es) | 1994-11-10 | 2004-12-01 | Millennium Pharmaceuticals, Inc. | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. |
AU4270596A (en) * | 1994-12-23 | 1996-07-19 | Celltech Therapeutics Limited | Human phosphodiesterase type ivc, and its production and use |
US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
WO1997009325A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
MX9802383A (es) * | 1995-10-02 | 1998-08-30 | Hoffmann La Roche | Derivados de pirimidina como antagonistas del receptor 5ht26. |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526245D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526243D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US5785354A (en) * | 1996-05-06 | 1998-07-28 | Temtec, Inc. | Self-expiring identification band |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) * | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
BR9807305A (pt) | 1997-02-05 | 2000-05-02 | Warner Lambert Co | Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular. |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9806739D0 (en) * | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
MEP13408A (en) * | 2001-05-29 | 2010-06-10 | Bayer Schering Pharma Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
CA2463989C (en) * | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
NZ539823A (en) * | 2002-11-28 | 2008-04-30 | Schering Aktiengessellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2002
- 2002-05-23 ME MEP-134/08A patent/MEP13408A/xx unknown
- 2002-05-23 NZ NZ529654A patent/NZ529654A/en unknown
- 2002-05-23 EP EP02738100A patent/EP1392662B1/de not_active Expired - Lifetime
- 2002-05-23 KR KR1020037015597A patent/KR100874791B1/ko not_active IP Right Cessation
- 2002-05-23 AU AU2002312933A patent/AU2002312933B2/en not_active Ceased
- 2002-05-23 ES ES02738100T patent/ES2320204T3/es not_active Expired - Lifetime
- 2002-05-23 BR BR0209774-5A patent/BR0209774A/pt not_active IP Right Cessation
- 2002-05-23 CA CA002449118A patent/CA2449118A1/en not_active Abandoned
- 2002-05-23 MX MXPA03010810A patent/MXPA03010810A/es active IP Right Grant
- 2002-05-23 RU RU2003136080/04A patent/RU2330024C2/ru active
- 2002-05-23 WO PCT/EP2002/005669 patent/WO2002096888A1/de active Application Filing
- 2002-05-23 DE DE50213202T patent/DE50213202D1/de not_active Expired - Lifetime
- 2002-05-23 PL PL02367130A patent/PL367130A1/xx not_active Application Discontinuation
- 2002-05-23 IL IL15912002A patent/IL159120A0/xx unknown
- 2002-05-23 CN CNB02814886XA patent/CN100480242C/zh not_active Expired - Fee Related
- 2002-05-23 RS YUP-947/03A patent/RS94703A/sr unknown
- 2002-05-23 AT AT02738100T patent/ATE420077T1/de not_active IP Right Cessation
- 2002-05-23 JP JP2003500067A patent/JP4291135B2/ja not_active Expired - Fee Related
- 2002-05-29 US US10/156,759 patent/US7235561B2/en not_active Expired - Fee Related
- 2002-05-29 AR ARP020102001A patent/AR036035A1/es unknown
-
2003
- 2003-11-28 NO NO20035298A patent/NO327129B1/no not_active IP Right Cessation
- 2003-12-23 HR HR20031081A patent/HRP20031081A2/hr not_active Application Discontinuation
- 2003-12-26 CO CO03112613A patent/CO5540316A2/es not_active Application Discontinuation
-
2004
- 2004-05-11 US US10/842,419 patent/US7291624B2/en not_active Expired - Fee Related
-
2007
- 2007-06-26 US US11/819,307 patent/US7598260B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL159120A0 (en) | 2004-05-12 |
US7291624B2 (en) | 2007-11-06 |
KR20040030645A (ko) | 2004-04-09 |
RU2330024C2 (ru) | 2008-07-27 |
JP2004535414A (ja) | 2004-11-25 |
PL367130A1 (en) | 2005-02-21 |
CN1633419A (zh) | 2005-06-29 |
AR036035A1 (es) | 2004-08-04 |
CN100480242C (zh) | 2009-04-22 |
JP4291135B2 (ja) | 2009-07-08 |
HRP20031081A2 (en) | 2005-10-31 |
NO20035298D0 (no) | 2003-11-28 |
US7598260B2 (en) | 2009-10-06 |
ATE420077T1 (de) | 2009-01-15 |
US20080039447A1 (en) | 2008-02-14 |
NZ529654A (en) | 2005-12-23 |
CO5540316A2 (es) | 2005-07-29 |
US20040224966A1 (en) | 2004-11-11 |
MEP13408A (en) | 2010-06-10 |
NO327129B1 (no) | 2009-04-27 |
MXPA03010810A (es) | 2004-03-22 |
DE50213202D1 (de) | 2009-02-26 |
CA2449118A1 (en) | 2002-12-05 |
US7235561B2 (en) | 2007-06-26 |
EP1392662A1 (de) | 2004-03-03 |
AU2002312933B2 (en) | 2007-12-06 |
RU2003136080A (ru) | 2005-05-20 |
RS94703A (en) | 2007-02-05 |
BR0209774A (pt) | 2004-06-01 |
EP1392662B1 (de) | 2009-01-07 |
WO2002096888A1 (de) | 2002-12-05 |
KR100874791B1 (ko) | 2008-12-18 |
US20040102630A1 (en) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2320204T3 (es) | Pirimidinas inhibidoras de cdk, su preparacion y su utilizacion como medicamentos. | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
PE20211411A1 (es) | Compuestos de anillo fusionado | |
AR063529A1 (es) | Compuestos de pirazolina | |
AR065556A1 (es) | Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida | |
AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
CO6270328A2 (es) | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR012825A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos | |
HRP20030657B1 (en) | 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors | |
AR035362A1 (es) | Compuestos inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona, composiciones farmaceuticas, y metodos de tratamiento con dichos compuestos | |
AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
AR049551A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa | |
UY26899A1 (es) | Derivados de pirazol fusionados | |
AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
AR066348A1 (es) | Inhibidores de las iap | |
AR025975A1 (es) | Compuestos quimicos. | |
AR063240A1 (es) | Derivados de n-aril pirazol,composiciones farmaceuticas que los contienen y usos para el tratamiento de la diabetes tipo2,y enfermedades relacionadas. | |
AR015269A1 (es) | Compuesto amidinico y composicion farmaceutica, inhibidor de la coagulacion sanguinea e inhibidor del factor xa que lo comprenden | |
CY1111697T1 (el) | Νεες συνθεσεις οι οποιες περιεχουν ενωσεις κινολινης | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
CO5690551A2 (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 |